Evidence map›Paper›PMID 40356286›Full record

ArticlemAbs2025

Structural and biochemical differences between non-catalytic and catalytic antibodies.

Taizo Uda, Ryuichi Kato, Yasuteru Shigeta, Shun Hirota, Jun Kobayashi, Hisashi Yoshida, Masato Tsuyuguchi, Kowit Hengphasatporn, Moe Tsujita, Hiroaki Taguchi and 1 more

Abstract read
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Taizo UdaResearch Center for GLOBAL/LOCAL Infectious Diseases, Oita University, Oita-shi, Oita, Japan.ORCID 0000-0001-8146-7902
Ryuichi KatoStructural Biology Research Center, Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan.
Yasuteru ShigetaCenter for Computational Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Shun HirotaDivision of Materials Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Takayama, Ikoma, Nara, Japan.
Jun KobayashiStructural Biology Research Center, Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan.
Hisashi YoshidaStructural Biology Research Center, Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan.
Masato TsuyuguchiStructural Biology Research Center, Photon Factory, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan.
Kowit HengphasatpornCenter for Computational Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Moe TsujitaGraduate School of Engineering, Oita University, Oita-shi, Oita, Japan.
Hiroaki TaguchiFaculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.ORCID 0000-0003-3183-6380
Emi HifumiResearch Center for GLOBAL/LOCAL Infectious Diseases, Oita University, Oita-shi, Oita, Japan.ORCID 0000-0002-5123-3846

Funding

KAKENHI JP16H02282KAKENHI JP23K17980the Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) from AMED JP21AM0101083
6 · The paper itself

Abstract

A conventional antibody can be converted into its catalytic counterparts by deleting Pro95 in the CDR-3 of human and mice antibody light chains, as previously reported. T99wt is a naturally occurring human antibody light chain that we transformed into its catalytic antibody using Pro95 deletion. In peptidase activity tests, T99wt exhibited a low catalytic activity against a synthetic peptide Arg-pNA and hardly cleaved amyloid-β peptide. In contrast, the engineered variant (T99-Pro95(-)) demonstrated significant catalytic activity, effectively cleaving both Arg-pNA substrate and amyloid-β peptides. In this study, the structural basis for the acquisition of enzymatic function through Pro95 deletion in the CDR-3 region of the light chain was elucidated using X-ray crystallography and molecular dynamics (MD) simulations. X-ray crystallography revealed that Pro95 deletion substantially reduces the distance between Asp1 and His93-key residues for catalytic activity - from 9.56 Å in T99wt to 3.84 Å in T99-Pro95(-). The observed decrease in distance indicates a strong interaction between Asp1(Oδ1) and His93(Nε2), contributing to the formation of an active site in T99-Pro95(-). MD simulations revealed that the entire structure exhibits slight fluctuations and adopts various configurations upon the removal of Pro95. In particular, when His residues in the catalytic region are fully deprotonated, Asp1, His93, and Ser27a transiently come into close proximity, enabling the formation of a functional catalytic triad. Catalytic antibodies can be made starting from just the amino acid sequence of a desired mAb, which may be available in databases such as OAS or IMGT. Therefore, our finding represents a significant technological advancement.

Indexed as

Antibodies, CatalyticImmunoglobulin Light ChainsAmyloid beta-PeptidesAnimalsCatalytic DomainCrystallography, X-RayHumansMiceMolecular Dynamics SimulationAmyloid beta-PeptidesAntibodies, CatalyticImmunoglobulin Light Chainsamyloid-betaCatalytic antibodymolecular dynamicspro95 residue deletiontau-proteinX-ray crystallography

Identifiers

PMID40356286
PMCPMC12077472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.